Dr. Rob Beanlands is the Vered Chair and Division Head of Cardiology at the University of Ottawa Heart Institute in Ottawa, Ontario, Canada. He is also Director of its National Cardiac PET Centre, and Professor in the University’s Division of Cardiology in the Department of Medicine, in the Department of Radiology, and in the Department of Cellular and Molecular medicine.
Dr. Rob Beanlands is a founding member of ASNC, a member of its Board of Directors and longtime associate editor of the Journal of Nuclear Cardiology. He has served on the education, finance, audit, and quality committees; and ASNC’s PET Task Force, appearing as featured faculty at several education programs. He has also served as Program Chair and Vice Program Chair of ASNC’s Annual Scientific Session in 2011 and 2012, respectively.
During his tenure as president, Dr. Beanlands will focus on appropriate use criteria, maximizing the value of nuclear cardiology testing to provide high quality, cost-effective cardiac care, and member leadership development and expanding ASNC’s international footprint. A key part of his mission is to educate the cardiovascular imaging community, including referring physicians, on the expanding applications of nuclear cardiology such as cardiac amyloidosis and the important role to diagnose and prognosticate the disease; and increase positron emission tomography (PET) training through workshops and online curriculum demonstrating best practices for blood flow measurements. In addition, he will continue to expand and utilize data from the ImageGuide Registry®, the nation’s first cardiovascular nuclear imaging data registry and Qualified Clinical Data Registry (QCDR), to improve laboratory quality and efficiency, optimize patient radiation exposure, minimize downstream costs and improve patient care and safety.
He is enthusiastic about the evolution of multimodality imaging and nuclear cardiology’s role in patient management to guide therapy. “The key aspect [of nuclear cardiology] is in the guiding therapy,” he says. “As new therapies emerge so, too, will follow the strength of nuclear imaging, which enables the understanding of biological processes in the heart and the vasculature. This helps us to decide the treatments for patients that may improve their outcomes.” Nuclear cardiology studies continue to play an increasingly important role in the new millennium, in the noninvasive diagnosis of coronary artery disease, the assessment of the pumping function of the heart, and in the prediction of outcomes in patients with heart disease.